Reports Q2 revenue $22.4B, consensus $22.31B. “Johnson & Johnson’s second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and adjusted operational earnings per share growth,” said Joaquin Duato, Chairman and CEO. “With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and continued expansion of newly launched products, including ACUVUE OASYS MAX 1-Day contact lenses and our VARIPULSE platform, we have a strong foundation for near and long-term growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Stock Market News Today, 7/17/24 – Futures Down After a Strong Session
- 3 Reasons Johnson & Johnson (NYSE:JNJ) Is an Attractive Dividend Growth Stock
- Johnson & Johnson (JNJ) Q2 Earnings Preview: Here’s What to Expect
- Johnson & Johnson Stock (NYSE:JNJ): The Best Buying Opportunity in Over a Decade?
- Stock Market News Today, 7/15/24 – Indices Close Higher amid Powell’s Praise